Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,244 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunologic Deficiency Syndromes Clear all
Terminated Not applicable Interventional

Targeting Non-virally Suppressed Adults With Alcohol Use Disorder in HIV Primary Care

NCT04280068
View directory record Official record
Conditions
Alcohol Dependence, HIV/AIDS
Interventions
Clinician Guide (CG), Clinician Guide plus HealthCall
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Acupuncture and Moxa: A Randomized Clinical Trial for Chronic Diarrhea in HIV Patients

NCT00010491
View directory record Official record
Conditions
HIV Infections
Interventions
Acupuncture, Moxibustion
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Not applicable Interventional

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)

NCT00002060
View directory record Official record
Conditions
HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT03821038
View directory record Official record
Conditions
Sepsis, Severe
Interventions
CYT107, Placebos
Biological · Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

NCT00771810
View directory record Official record
Conditions
Thrombocytopenia, Neutropenia, Lymphopenia, Anemia
Interventions
TXA127, Placebo
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

A Study of Disease Progression and Anti-HIV Treatments

NCT00001068
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 4 Interventional

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

NCT00246610
View directory record Official record
Conditions
HIV Infection
Interventions
Nelfinavir mesylate, 625 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Jacksonville, Florida • Miami, Florida • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 27, 2026, 5:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

ID and Testing Via Friendship Networks

NCT00841360
View directory record Official record
Conditions
Asymptomatic HIV, HIV Infections
Interventions
Index Recruiter, Friendship Network Member
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 24 Years · Female only
Enrollment
535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 27, 2026, 5:20 PM EDT
Terminated Not applicable Interventional

Intrauterine Insemination In HIV-Discordant Couples

NCT01173276
View directory record Official record
Conditions
HIV-1, Fertility, Infertility
Interventions
Sperm Washing with Intrauterine Insemination (IUI)
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 27, 2026, 5:20 PM EDT
Not listed Phase 1 Interventional

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

NCT03588715
View directory record Official record
Conditions
HIV, HIV/AIDS, HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
Drug
Lead sponsor
Luis Montaner
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 27, 2026, 5:20 PM EDT
Completed No phase listed Observational

Attitudes and Beliefs and the Steps of HIV Care

NCT00749840
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Not applicable Interventional

Directly Observed Therapy for HIV Infected Adolescents

NCT00259389
View directory record Official record
Conditions
HIV Infections
Interventions
Directly observed therapy (DOT)
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 27, 2026, 5:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

NCT05576350
View directory record Official record
Conditions
Risk Behavior, Alcohol Use Disorder, HIV Infections
Interventions
Smartphone Based Alcohol Monitoring (SAM), Tracking and Reducing Alcohol Consumption (TRAC), TRAC-ER
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 35 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HIV Prevention for Youth With Severe Mental Illness

NCT00496691
View directory record Official record
Conditions
HIV Infections
Interventions
Family-based HIV prevention program
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
718 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 3 Interventional

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

NCT00002378
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
97
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 1Phase 2 Interventional

ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects

NCT00004578
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
10
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 27, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome

NCT00527878
View directory record Official record
Conditions
JOB's Syndrome, Hyper-IgE Recurrent Infection Syndrome, Immune Deficiency
Interventions
Ranitidine, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

NCT00002226
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
SU5416
Drug
Lead sponsor
SUGEN
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 5:20 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Skin Immunity Sample Collection Involving Blisters and Biopsies

NCT03921515
View directory record Official record
Conditions
Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Interventions
Blister induction, Skin Biopsies
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

NCT02715479
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir, BMS955176
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 27, 2026, 5:20 PM EDT
Enrolling by invitation No phase listed Observational

Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home

NCT06488846
View directory record Official record
Conditions
HIV Infections
Interventions
INVITE-Home, Clinic-Administered LAI-ART, Oral ART
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 4 Interventional Results available

HIV Persistence and Viral Reservoirs

NCT01025427
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Raltegravir, tenofovir/emtricitabine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alcohol Monitor Validation

NCT03617705
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA App, Skyn Monitor Lab Session 2
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 27, 2026, 5:20 PM EDT
Completed Phase 4 Interventional Results available

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

NCT00735072
View directory record Official record
Conditions
HIV Infection
Interventions
Placebo, Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 27, 2026, 5:20 PM EDT